Why joint implant infections are more common in people with bone sarcoma
Studies tissue and blood samples to understand implant infections in skeletal sarcoma patients.
Plain-language title generated from the registry record
Registry title: Implant-Related Infections in Patients With Skeletal Sarcomas
Key facts
- Where
- Gothenburg, SwedenSee the site
Where in Sweden
- Ortopedi, Sahlgrenska University HospitalGothenburg, SwedenNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vastra Gotaland Region
- Trial code
- NCT07264296
- Record updated
- 4 December 2025
- Original description
The aim of this observational study is to gain knowledge on the microbial and immunological factors behind implant-related infections in patients with skeletal sarcoma.Read full original descriptionShow less
Implant-related Infections in Patients With Skeletal Sarcomas
The aim of this observational study is to gain knowledge on the microbial and immunological factors behind implant-related infections in patients with skeletal sarcoma.
The main research question the project aims to answer is:
• Are immunological factors more important than microbial factors in peri-prosthetic joint infections in orthopaedic oncology patients?
Patients with skeletal sarcoma planned for primary surgery (tumour resection and replacement with a megaprosthesis) will be sampled intraoperatively to obtain a cross-section bone tissue slice at the resection margin, three soft tissue biopsies and joint fluid (if possible). Patients who develop a peri-prosthetic joint infection after their primary surgery will be sampled in a similar manner during revision surgery.
An additional group of patients with periprosthetic joint infection of a hip or knee prosthesis due to osteoarthritis will be sampled during their revision surgery (bone biopsies, soft tissue biopsies and joint fluid, if possible).
Blood samples will be taken from all patients pre-operatively for extensive biochemical and cellular analyses.
Researchers will compare periprosthetic tissues before and after infection. Further, periprosthetic infected tissues in patients treated for skeletal sarcoma will be compared to periprosthetic infected tissues in patientens treated for osteoarthritis. This will be done to attempt to identify host and microbial mechanisms responsible for the increased infection rate in patients with a megaprosthesis due to skeletal sarcoma (infection incidence rate up to 30%) compared to patients with a hip or knee prosthesis due to osteoarthritis (infection incidence rate 1-2%).
Inclusion: Patients diagnosed with skeletal sarcoma planned for primary surgery with resection of tumour and replacement with a megaprosthesis; Patients operated with a megaprosthesis due to skeletal sarcoma who develop a peri-prosthetic joint infection (PJI); Patients diagnosed with PJI after total hip or knee replacement due to osteoarthritis.
Exclusion: Patients in the PJI group who have a total hip or knee replacement are excluded if they use immunomodulary medication or have a immunodeficiency; None in the group of patients with skeletal sarcoma.